Old Web
English
Sign In
Acemap
>
authorDetail
>
A. Eli Gabayan
A. Eli Gabayan
Pathology
Medicine
Tolerability
in patient
Melanoma
2
Papers
7
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors.
2018
Journal of Clinical Oncology
Daniel A. Vaena
Jorge Chaves
Nicholas J. Vogelzang
Marc R. Matrana
A. Eli Gabayan
Matthew J. Riese
Daniel C. Cho
Mary Tagliaferri
Jonathan Zalevsky
Sunny Xie
Ute Hoch
Ahsan Naqi Rizwan
Sandra Aung
Michael Imperiale
James K. Schwarz
Show All
Source
Cite
Save
Citations (3)
A phase 1b/2 study of INCB039110 + nab-paclitaxel (N) and gemcitabine (G) in patients (pts) with advanced solid tumors and pancreatic cancer (PC).
2017
Journal of Clinical Oncology
Gregory L. Beatty
Safi Shahda
J. Thaddeus Beck
Nikhil Uppal
Steven J. Cohen
Ross C. Donehower
A. Eli Gabayan
Albert Assad
Julie Switzky
Huiling Zhen
Daniel D. Von Hoff
Show All
Source
Cite
Save
Citations (4)
1